AI Medical Imaging Reconstruction Patents

AI medical imaging reconstruction patents cover accelerated-MRI-reconstruction innovations; low-dose-CT/PET innovations; denoising/super-resolution innovations; and deep-learning-recon-algorithm and §101/FDA innovations — with IP held by imaging-equipment majors and AI-imaging specialists (in a field using AI to RECONSTRUCT the medical image itself, not to diagnose it). WHY AI MEDICAL IMAGING RECONSTRUCTION: this is DISTINCT from AI DIAGNOSIS (which reads a finished image to find disease) — AI RECONSTRUCTION uses deep learning at an EARLIER stage to turn the scanner's RAW data into the IMAGE itself, far better and faster: ACCELERATING MRI (an MRI that took ~30+ minutes can be reconstructed from much less data in MINUTES — huge for throughput, cost, and patient comfort), enabling LOW-DOSE CT/PET (reconstructing diagnostic-quality images from LESS radiation or contrast — patient safety), and DENOISING/super-resolving images; it improves image quality WHILE cutting scan time, radiation dose, and cost — a major efficiency/safety advance in radiology. MAJOR HOLDERS: GE HEALTHCARE (AIR Recon DL — deep-learning MRI reconstruction), SIEMENS HEALTHINEERS, PHILIPS, SUBTLE MEDICAL (SubtleMR/SubtlePET), plus academic IP. Accelerated MRI reconstruction, low-dose CT/PET, denoising/super-resolution, deep-learning recon algorithms, and §101/FDA are the core reconstruction patent domains — and accelerated reconstruction, low-dose, denoising, and recon algorithms are the open whitespace.

Accelerated-MRI-reconstruction innovations; low-dose-CT/PET innovations; denoising/super-resolution innovations; and deep-learning-recon-algorithm innovations represent core AI-reconstruction patent domains — and reconstructing high-quality images from less data, dose, or noise is the foundational, high-value capability. ACCELERATED-MRI-RECONSTRUCTION PATENTS: the marquee application — reconstructing high-quality MRI images from UNDERSAMPLED k-space data (taking FEWER measurements to scan FASTER, then using deep learning to fill in/reconstruct the missing data) — cutting scan times dramatically; accelerated-reconstruction methods (deep-learning recon from sparse data, undersampling patterns) are core, high-value IP (faster MRI is a major throughput/cost/comfort win — GE AIR Recon DL). LOW-DOSE-CT/PET RECONSTRUCTION PATENTS: reconstructing DIAGNOSTIC-quality CT or PET images from LOWER radiation DOSE or less CONTRAST agent (deep learning recovers image quality lost to dose reduction) — improving patient SAFETY; low-dose reconstruction methods are high-value IP (radiation/contrast reduction is a major safety driver). DENOISING / SUPER-RESOLUTION PATENTS: deep-learning DENOISING (removing noise to allow faster/lower-dose acquisition) and SUPER-RESOLUTION (enhancing resolution); denoising/super-resolution methods are high-value (broadly applicable across modalities). DEEP-LEARNING-RECON-ALGORITHM PATENTS: the model ARCHITECTURES — UNROLLED optimization networks (embedding the imaging physics into the network), physics-informed models, and generative models — mapping raw/sparse sensor data to images; recon-algorithm methods are core IP (the algorithm is the invention — and physics-informed recon is distinctive). Accelerated MRI, low-dose CT/PET, denoising/super-resolution, and recon algorithms are the highest-value core IP because reconstructing better images from less data/dose/noise is exactly what AI reconstruction delivers.

§101-eligibility advantages; FDA/regulatory innovations; hallucination/safety innovations; and scanner-integration and workflow innovations represent additional AI-reconstruction patent domains — and reconstruction's stronger patent-eligibility, plus regulatory safety, are where this differs favorably from diagnostic AI. §101-ELIGIBILITY ADVANTAGE PATENTS: a key strategic point — AI image RECONSTRUCTION (transforming raw SENSOR/scanner data into an image — a concrete technical transformation of a signal) is often MORE clearly PATENT-ELIGIBLE than AI DIAGNOSIS (which can be attacked as an abstract mental process/diagnosis under Alice/Mayo, like AI-radiology faces); reconstruction is a tangible signal-processing/imaging-physics transformation tied to a machine (the scanner) — claim it as a concrete technical method (specific reconstruction process, physics integration, scanner-tied transformation) to leverage this eligibility advantage over diagnostic claims. FDA / REGULATORY PATENTS: reconstruction software is a regulated MEDICAL device (SaMD) — and a critical concern is that it must NOT HALLUCINATE features or REMOVE real pathology (a deep-learning recon could 'invent' a clean-looking image that hides disease); methods ensuring regulatory-grade reliability, validation, and pathology preservation are valuable IP (and FDA clearance is essential). HALLUCINATION / SAFETY PATENTS: the central safety risk — preventing the AI from creating ARTIFACTS, hallucinating structures, or smoothing away real findings; methods detecting/preventing hallucination, uncertainty quantification, and guaranteeing diagnostic content is preserved are high-value, important IP (clinical trust depends on it). SCANNER-INTEGRATION / WORKFLOW PATENTS: integrating reconstruction into the scanner pipeline (on-scanner or cloud), vendor-specific vs vendor-neutral, and workflow; integration methods are valuable. §101 eligibility advantage, FDA/regulatory, hallucination/safety, and scanner integration are the highest-value strategic IP because reconstruction's stronger eligibility, plus provable safety/reliability, are exactly what make this AI both patentable and clinically deployable.

AI medical imaging reconstruction startup IP strategy must navigate GE/Siemens/Philips (imaging-equipment majors with strong recon and on-scanner-integration IP) and Subtle Medical/academic portfolios, decades of image-reconstruction/signal-processing prior art (reconstruction is mature — the DEEP-LEARNING recon, acceleration, and low-dose advances are the novelty), the §101 ADVANTAGE (reconstruction is more clearly eligible than diagnosis — a real plus to leverage), the scanner-integration reality (on-scanner recon favors the equipment majors; vendor-NEUTRAL/cloud recon is the whitespace for startups — Subtle Medical model), the hallucination/safety imperative (the key clinical risk and FDA concern), the FDA/clinical path, the training-data moat (paired raw/image data), and a landscape where accelerated reconstruction, low-dose, denoising, recon algorithms, and safety are the durable assets; understand that classical reconstruction is mature and majors hold on-scanner IP, so the durable IP is in deep-learning recon algorithms (accelerated/low-dose/denoising), vendor-neutral integration, hallucination-prevention/safety, and training methods — with algorithms/data and the §101 advantage often the real leverage, and that image quality/acceleration, safety (no hallucination), FDA clearance, and integration matter as much as patents; identify whitespace in vendor-neutral recon, low-dose, and safety. AI-RECONSTRUCTION STARTUP IP STRATEGY: DEEP-LEARNING RECON (ACCELERATED/LOW-DOSE/DENOISING), VENDOR-NEUTRAL INTEGRATION, HALLUCINATION-PREVENTION/SAFETY, AND TRAINING METHODS ARE THE IP: patent deep-learning reconstruction algorithms, low-dose/accelerated methods, denoising/super-resolution, vendor-neutral integration, and hallucination-prevention/safety — claim as concrete technical signal-processing/imaging methods (leverage §101); LEVERAGE THE §101 ELIGIBILITY ADVANTAGE: reconstruction (transforming raw scanner data into an image — a concrete technical transformation tied to a machine) is MORE clearly patent-eligible than diagnosis (which faces Alice/Mayo abstract-idea attacks) — claim the technical reconstruction process to capture this advantage; VENDOR-NEUTRAL/CLOUD RECON IS THE STARTUP WHITESPACE: equipment majors (GE/Siemens/Philips) own on-scanner recon — startups win with VENDOR-NEUTRAL/cloud reconstruction that works across scanners (Subtle Medical model) — distinctive IP and business model; HALLUCINATION-PREVENTION/SAFETY IS THE KEY CLINICAL RISK AND IP: deep-learning recon must NOT invent features or remove pathology — methods guaranteeing pathology preservation, detecting/preventing hallucination, and uncertainty quantification are high-value, trust-critical IP; ACCELERATED MRI + LOW-DOSE CT ARE THE HIGH-VALUE APPLICATIONS: faster MRI (throughput/cost/comfort) and lower-dose CT (safety) are the clearest value — application-specific recon IP is valuable; RECON ALGORITHM (PHYSICS-INFORMED/UNROLLED) IS CORE: embedding imaging physics into the network is distinctive, defensible algorithm IP; TRAINING DATA IS OFTEN A MOAT: paired raw-sensor/high-quality-image datasets to train recon models are valuable (and hard to get); FDA/CLEARANCE GATES DEPLOYMENT: reconstruction is regulated SaMD — clearance + validation essential; IMAGE-QUALITY/SAFETY/FDA/INTEGRATION MATTER AS MUCH AS PATENTS: image quality/acceleration, no-hallucination safety, FDA clearance, and integration drive value; WHEN TO PATENT: NOVEL RECON/ACCELERATION/LOW-DOSE/SAFETY WITH MEASURED PERFORMANCE: file once a method shows measured results (acceleration factor/scan-time + image quality/SNR + dose reduction + diagnostic-content preservation/no-hallucination + generalization across scanners) — measured acceleration/dose reduction, image quality, and safety (pathology preservation) are the critical AI-reconstruction IP metrics; KEY FTO CHECKLIST: GE HealthCare (AIR Recon DL)/Siemens Healthineers/Philips on-scanner recon; Subtle Medical (vendor-neutral); academic recon prior art; accelerated MRI reconstruction (undersampled k-space/deep-learning recon); low-dose CT/PET reconstruction (dose/contrast reduction); denoising/super-resolution; deep-learning recon algorithm (unrolled/physics-informed/generative); §101 eligibility (reconstruction vs diagnosis — technical transformation); FDA/SaMD/regulatory; hallucination/pathology-preservation/safety/uncertainty; scanner integration (on-scanner vs vendor-neutral/cloud); paired raw/image training data (moat).